Sensus Healthcare (NASDAQ:SRTS) Price Target Raised to $11.00 at HC Wainwright

Sensus Healthcare (NASDAQ:SRTS) had its price objective raised by HC Wainwright from $10.00 to $11.00 in a research note published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Maxim Group upped their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday.

Sensus Healthcare Trading Up 10.1 %

Shares of SRTS opened at $8.41 on Monday. Sensus Healthcare has a 1-year low of $2.02 and a 1-year high of $8.69. The firm has a market capitalization of $137.83 million, a price-to-earnings ratio of 14.60 and a beta of 1.04. The firm’s 50-day moving average price is $6.37 and its 200-day moving average price is $5.97.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Truvestments Capital LLC purchased a new stake in Sensus Healthcare in the third quarter worth about $32,000. Chapin Davis Inc. purchased a new stake in shares of Sensus Healthcare in the 2nd quarter worth approximately $53,000. Geode Capital Management LLC increased its position in Sensus Healthcare by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after buying an additional 11,525 shares in the last quarter. Sachetta LLC raised its stake in Sensus Healthcare by 12.9% during the second quarter. Sachetta LLC now owns 118,354 shares of the company’s stock valued at $631,000 after buying an additional 13,544 shares during the last quarter. Finally, XTX Topco Ltd boosted its holdings in Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after acquiring an additional 13,619 shares in the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.